Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 5/20 | 0.70 |
| ▸ | SYK | P43405 | 2/20 | 0.58 |
| ▸ | GALR2 | O43603 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361007 | 1.00 | VCP (0.70) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL7390829 | 0.95 | VCP (0.70) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL7355608 | 0.95 | VCP (0.70) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL13677650 | 0.86 | VCP (0.52) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL13677860 | 0.83 | TLR4 (0.54) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL29727003 | 0.83 | VCP (1.00) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL807768 | 0.83 | VCP (1.00) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL793160 | 0.83 | VCP (1.00) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL7398936 | 0.83 | VCP (0.52) | VCPSYKGALR2ALDH1A1EGFR | |
| SCHEMBL7358653 | 0.83 | VCP (0.49) | VCPSYKGALR2ALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5274002-A | 1-Oxy- or -thio-2-cycloalkyloxy-4-carboxyalkylene benzene derivatives | WARNER-LAMBERT COMPANY (US) | 1993-12-28 | — | — | US | claimed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1512678-A1 | Process for preparing optically active nitro compounds and cyano compounds | Kanto Kagaku Kabushiki Kaisha (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
| US-5710180-A | TREATING ALLERGIC AND INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0714397-A4 | — | — | 1996-06-26 | — | — | EP | disclosed |
| EP-0714397-A1 | PHENETHYLAMINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0538384-A4 | OXAMIDES | SMITHKLINE BEECHAM CORP (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5393788-A | Phenylalkyl oxamides | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1995005386-A1 | PHENETHYLAMINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-23 | — | — | WO | disclosed |
| US-5274002-A | 1-Oxy- or -thio-2-cycloalkyloxy-4-carboxyalkylene benzene derivatives | WARNER-LAMBERT COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0538384-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000968-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
| US-4971959-A | Trisubstituted phenyl analogs having activity for congestive heart failure | WARNER-LAMBERT COMPANY (US) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | NOS1, NOS2, NOX1 | VCP 4367/4885SYK 1723/4885GALR2 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.